Fundraising FoxShinsei Capital Partners
Venture capitalTokyo · Pre-Seed–Late Stage
Also known as 新生キャピタルパートナーズ株式会社
Find your way into Shinsei Capital Partners
Sign up to see every warm intro you have to Shinsei Capital Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Shinsei Capital Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
The firm sees Japan's life sciences sector as globally competitive thanks to sustained research by universities, institutions, and pharmaceutical companies. Its mission is to financially support these research outcomes to bring innovative medicines to patients and drive practical commercialization. Managing the New Life Science No.1 fund, it invests in drug-discovery ventures across company creation, seed, early, middle, and later stages, drawing on decades of combined expertise in finance and drug development to enable technology-driven innovation in healthcare.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 6 of 7 portfolio companiesBiotech ×6Deep Tech ×4Healthtech ×4Medical Devices ×3AI & Machine Learning ×1Digital Health ×1
HQs:Japan×6
Investments · 7 tracked
founders shown can be your intro pathAlphaNavi Pharma is a pharmaceutical company developing new drugs (Nav channel inhibitors) for patients suffering from chronic pain and neurological disorders.
BiotechDigital HealthHealthtech京都市, JP
小山田義博Yoshihiro Oyamada(Representative Director)
Co-investorsKyoto University Innovation Capital
Cancer therapeutics development (RNA regulation abnormalities).
Co-investorsKyoto University Innovation CapitalNippon Venture CapitalSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.JAFCO Group
FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases.
BiotechDeep TechMedical DevicesFujisawa, JP
福田 将虎(Founder & Scientific Advisor)高橋 信明(代表取締役社長・CEO (President & CEO))
MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics.
BiotechDeep TechHealthtechTokyo, JP
Hiroaki Suga(Co-founder; Professor, University of Tokyo)inJunichi Takagi(Co-founder; Director & Professor, Osaka University)Masuhiro Kato(Representative Director & President)inIgarashi(Chief Operating Officer)
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
AI & Machine LearningBiotechDeep TechMedical DevicesKawasaki, JP
Shingo Nakamura(CEO)in
Co-investorsGlobal BrainKDDI Open Innovation FundNippon Venture CapitalSMBC Venture Capital
TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services.
BiotechHealthtechMedical DevicesHiroshima, JP
松本 昌也(代表取締役社長)
Co-investorsHiroshima Venture Capital Co. Ltd.
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Co-investorsMedical Incubator Japan K.K.Nippon Venture CapitalSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.
Portfolio news
latest coverage across their companiesVeritas In Silico · biospace.com · Apr 15, 2026
Frequently asked questions
- How many investments has Shinsei Capital Partners made?
- Shinsei Capital Partners has 7 tracked investments.
- What stage does Shinsei Capital Partners invest at?
- Shinsei Capital Partners invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Shinsei Capital Partners focus on?
- Shinsei Capital Partners focuses on Biotech, Digital Health, Sector Agnostic.
- Where is Shinsei Capital Partners located?
- Shinsei Capital Partners is headquartered in Tokyo, JP.
- Who does Shinsei Capital Partners co-invest with?
- Shinsei Capital Partners most often shares deals with Nippon Venture Capital, SMBC Venture Capital, Kyoto University Innovation Capital, among 8 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
.png)
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.